Press Releases and Statements

This week, the Consumer Healthcare Products Association (CHPA) hosted its annual Regulatory, Scientific & Quality (RSQ) Conference. This year’s premier gathering of regulatory experts in the consumer healthcare industry was attended by more than 300 participants and included over 60 speakers and panelists.

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).

CHPA echoed concerns in a letter sent to the U.S. Food and Drug Administration by U.S. Reps. Bob Latta (OH-05), Debbie Dingell (MI-06), and Dan Crenshaw (TX-02), urging the Agency to ensure the simultaneous marketing provision of its proposed rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use is not included in a final rule.

The Consumer Healthcare Products Association Educational Foundation today released the following statement announcing the 2023 U.S. Self-Care Marketing Awards finalists. Winners will be announced at the Eighth Annual CHPA Educational Foundation Gala on November 15 at The Bellevue Hotel in Philadelphia. Specific awards will recognize the strategic innovation and marketing expertise of CHPA member companies in the OTC medicine, consumer medical device, and dietary supplement industries.

Today, the Consumer Healthcare Products Association (CHPA) submitted comments to the U.S. Food and Drug Administration (FDA) in response to a Citizen Petition from the Environmental Defense Fund (EDF) asking FDA to revoke the use of the colorant titanium dioxide (TiO2) in foods, including dietary supplements.

A recent national survey of adults conducted by the Bullfinch Group for CHPA further sheds light on consumer awareness, experiences, and perceptions of PE.

The Consumer Healthcare Products Association (CHPA) Educational Foundation and Family Dollar today announced the launch of a program to help Family Dollar shoppers make informed, educated choices about choosing and using over-the-counter (OTC) products and dietary supplements.

Bill proposes to make dietary supplements eligible expenses in FSA/HSA accounts, allowing consumers to use tax-preferred health savings to purchase wellness products.

Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today released the below statement following the U.S. Food and Drug Administration (FDA) approving Opill®

Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the following statement today in response to the U.S. Food and Drug Administration’s